On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes

被引:1
|
作者
Eren, Ayse [1 ]
Moon, David [2 ]
Curran, Timothy [3 ]
Luciani, Carla [1 ]
机构
[1] Vertex Pharmaceut, Pharmaceut Sci Engn & Mat Sci, 50 Northern Ave, Boston, MA 02210 USA
[2] Vertex Pharmaceut, Pharmaceut Sci Analyt Dev, 50 Northern Ave, Boston, MA 02210 USA
[3] Vertex Pharmaceut, Pharmaceut Sci Proc Chem, 50 Northern Ave, Boston, MA 02210 USA
关键词
N-NITROSAMINES; KINETICS; DECOMPOSITION;
D O I
10.1016/j.coche.2024.101030
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nitrosamine risk assessments are useful to identify processes and/or materials that exhibit legitimate safety concerns to evaluate appropriate actions and controls. Fundamental understanding of nitrosamine toxicity, formation pathways, fate, and purge aid risk quantification. In this work, available digital tools to aid nitrosamine risk assessments are reviewed. From structure-activity relationships through kinetic models to purge factors, these tools can shed light on the various aspects of a nitrosamine risk assessment. While tremendous progress has been made over the last few years, industry, academia, and government still need to focus on supporting science-based decisions and the integration of diverse tools to provide a holistic view of the nitrosamine risk.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance
    Selen, Arzu
    Dickinson, Paul A.
    Mullertz, Anette
    Crison, John R.
    Mistry, Hitesh B.
    Cruanes, Maria T.
    Martinez, Marilyn N.
    Lennernas, Hans
    Wigal, Tim L.
    Swinney, David C.
    Polli, James E.
    Serajuddin, Abu T. M.
    Cook, Jack A.
    Dressman, Jennifer B.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (11) : 3377 - 3397
  • [42] Uncertainty-conscious methodology for process performance assessment in biopharmaceutical drug product manufacturing
    Casola, Gioele
    Sugiyama, Hirokazu
    Siegmund, Christian
    Mattern, Markus
    AICHE JOURNAL, 2018, 64 (04) : 1272 - 1284
  • [43] An automated carcinogenic potency categorization approach for nitrosamine drug substance-related impurities
    Zhu, Jiazhou
    Qu, Yang
    Ye, Ning
    GREEN CHEMISTRY, 2024, 26 (07) : 3717 - 3721
  • [44] Data-driven anomaly detection and diagnostics for changeover processes in biopharmaceutical drug product manufacturing
    Zeberli, Anicia
    Badr, Sara
    Siegmund, Christian
    Mattern, Markus
    Sugiyama, Hirokazu
    CHEMICAL ENGINEERING RESEARCH & DESIGN, 2021, 167 : 53 - 62
  • [45] Assessing the Risk of Formation of Potential Genotoxic Degradation Products in a Small-Molecule Kinase Inhibitor Drug Substance and Drug Product
    Strege, Mark A.
    Osborne, Linda M.
    Hetrick, Evan M.
    Dill, Allison L.
    Jansen, Patrick J.
    Draper, Jerry R.
    Montgomery, Robert M.
    Buser, Jonas Y.
    Pack, Brian W.
    Smitka, Tim A.
    Baertschi, Steven W.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2015, 19 (11) : 1458 - 1464
  • [46] Control of the particle properties of a drug substance by crystallization engineering and the effect on drug product formulation
    Kim, S
    Lotz, B
    Lindrud, M
    Girard, K
    Moore, T
    Nagarajan, K
    Alvarez, M
    Lee, T
    Nikfar, F
    Davidovich, M
    Srivastava, S
    Kiang, S
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2005, 9 (06) : 894 - 901
  • [47] Degradation Pathway of a Taxane Derivative DS80100717 Drug Substance and Drug Product
    Tamura, Kousuke
    Ono, Makoto
    Kawabe, Takefumi
    Ohara, Motomu
    Yonemochi, Etsuo
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2020, 68 (04) : 392 - 397
  • [48] Case study in sustainable operations of commercial drug substance manufacturing through knowledge management and use of analytical tools
    Corrales, Mahalia
    Charaniya, Salim
    Villacorta, Michael
    Kulenovic, Fikret
    Calhoun, Kara
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [49] Modern analytical tools: Applications in drug product development
    Ulmschneider, M
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 23 : S17 - S18
  • [50] THE ROLE OF PHARMACOKINETICS IN DRUG PRODUCT DESIGN
    KWAN, KC
    HEIMLICH, KR
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1980, 6 (3-4) : 225 - 241